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Abstract
Influenza A virus causes annual epidemics which affect millions of people worldwide. A recent Influenza pandemic brought
new awareness over the health impact of the disease. It is thought that a severe inflammatory response against the virus
contributes to disease severity and death. Therefore, modulating the effects of inflammatory mediators may represent a
new therapy against Influenza infection. Platelet activating factor (PAF) receptor (PAFR) deficient mice were used to
evaluate the role of the gene in a model of experimental infection with Influenza A/WSN/33 H1N1 or a reassortant Influenza
A H3N1 subtype. The following parameters were evaluated: lethality, cell recruitment to the airways, lung pathology, viral
titers and cytokine levels in lungs. The PAFR antagonist PCA4248 was also used after the onset of flu symptoms. Absence or
antagonism of PAFR caused significant protection against flu-associated lethality and lung injury. Protection was correlated
with decreased neutrophil recruitment, lung edema, vascular permeability and injury. There was no increase of viral load
and greater recruitment of NK1.1+ cells. Antibody responses were similar in WT and PAFR-deficient mice and animals were
protected from re-infection. Influenza infection induces the enzyme that synthesizes PAF, lyso-PAF acetyltransferase, an
effect linked to activation of TLR7/8. Therefore, it is suggested that PAFR is a disease-associated gene and plays an
important role in driving neutrophil influx and lung damage after infection of mice with two subtypes of Influenza A.
Further studies should investigate whether targeting PAFR may be useful to reduce lung pathology associated with
Influenza A virus infection in humans.
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Introduction
Influenza A viruses belong to the Orthomixoviridae family of RNA
single-stranded, negative-sense viruses and cause epidemics,
leading to about 250,000 to 500,000 deaths and 3 to 5 million
severe cases annually worldwide [1,2]. The new Influenza A
H1N1 pandemic and the warning of a possible avian H5N1
pandemic increased the search for new vaccines and therapies
[2,3]. Antiviral drugs are an attractive possibility [4]. However, the
need for the initiation of treatment very early in the course of
infection [5] and the possibility of resistance suggest that novel
alternatives are necessary [6]. A promising approach to reduce flu
morbid is targeting immune molecules and cells related to disease
severity (reviewed in [7]).
The immune system is activated shortly after respiratory
epithelial cells have been infected by Influenza A. The single
stranded RNA of Influenza virus is sensed inside endosomes by
Toll like receptor 7 (TLR7) and TLR8 [8] and in cytoplasm by
the helicase RIG-I (retinoic acid inducible gene-I) [9] and the
inflammasome protein NLRP3 [10,11]. TLR3 recognizes a
intermediate of double strand RNA during Influenza replication
[12]. The recognition of infection leads to alveolar macrophage
recruitment and release of cytokines and chemokines with antiviral
and proinflammatory actions (reviewed by [13]). NK cells are
recruited in the first days of infection and are important for the
initiation of adaptive immune responses against Influenza virus
via IFN-c production [14]. Neutrophils are another important
leukocyte population involved in Influenza control [15]. Influenza
A virus is a potent stimulus for neutrophil activation in the lungs
and airways [16]. In addition to the antiviral action of neutrophils,
excessive lung inflammation may result in lung damage, disrup-
tion of alveolar epithelial barrier and fluid leakage that limits
respiratory capacity [17,18].
Platelet Activating Factor (PAF) is a phospholipid mediator
involved in many physiological and pathological conditions. The
synthesis of PAF under inflammatory conditions is mediated by an
acetyl-CoA:lyso-PAF acetyltransferase, named LysoPAFAT/
LPCAT2 [19]. PAF acts through a single G protein-coupled
receptor (PAFR) expressed in the plasma and nuclear mem-
branes of leukocytes, endothelial cells and platelets [20]. Several
PLoS Pathogens | www.plospathogens.org 1 November 2010 | Volume 6 | Issue 11 | e1001171
inflammatory events have been associated with the administra-
tion of PAF, including increase of vascular permeability and lung
edema [21], and leukocyte recruitment and activation [20,22].
Moreover, blockade of the PAFR has been shown to decrease
edema formation and/or leukocyte recruitment in several
models of inflammation [23,24,25]. Phosphatidilcoline oxidation
may also lead to the generation of PAF-like lipids that can
activate the PAFR [26] and that have been reported to trigger
lung injury after Influenza infection [27,28]. Furthermore,
upregulation of PAFR mRNA is seen during Influenza A virus
infection [29], which is consistent with its expression on
leukocytes and increase of these cells during Influenza A virus
infection. Because of the involvement of PAFR during inflam-
matory responses and its expression during Influenza A virus
infection, we hypothesized that PAFR activation may play an
important role in driving pulmonary inflammation and injury in
the context of Influenza A virus infection. To test our hypothesis,
PAFR deficient mice or mice treated with PAFR antagonists
were infected with two subtypes of Influenza A virus: a mouse-
adapted Influenza virus A/WSN/33 H1N1 or a less virulent
Influenza virus, H3N1. Our studies demonstrate that absence or
antagonism of PAFR protects against Influenza A related
lethality and inflammatory injury.
Results
Influenza A/WSN/33 H1N1-associated progressive weight
loss, pulmonary inflammation and death
In order to determine the lethal inoculum of Influenza A/
WSN/33 H1N1 virus in C57BL6/J mice, we infected the animals
with four different inocula – 103, 104, 105 and 106 PFU – and
accompanied them for 21 days after infection. Weight loss
occurred over time after infection with 105 and 106 PFU and
culminated with 100% death in 9 or 7 days, respectively. There
was substantial weight loss in mice infected with 104 PFU until the
eighth day of infection; thereafter, mice which survived (45%)
recovered weight gradually. There were no weight loss and deaths
associated with infection with 103 PFU (data not shown).
Based on the previous findings, we chose 104 as the mild
inoculum and 106 PFU as the lethal inoculum to assess pulmonary
inflammation associated with the infection. Since weight loss after
infection with 104 PFU was slower, we chose to evaluate lung
specimens at 3-day intervals from the first to the tenth day of
infection. On the other hand, shorter 2-days intervals were chosen
in the experiments with 106 PFU, from day one to five of infection.
We found substantial accumulation of neutrophils in BALF and
in lung tissue, as assessed by myeloperoxidase (MPO) activity and
histology, following infection (Figure 1). After 104 PFU, influx of
neutrophils in the lungs (Fig 1A) and airways (Fig 1B) was first
observed at day 4 after infection and returned to basal levels at day
10. When infected with the lethal inoculum (106 PFU), neutrophil
infiltration in the lungs and BAL fluid was already detectable at
day 1 and was more pronounced than with the lower inoculum
(Figure 1 D,E). Pulmonary infiltration tended to resolve by day 5
after lethal infection. Consistent with the early peak of neutrophil
accumulation at one day after infection with the lethal inoculum,
mRNA expression of LPAFAT/LPAFAT2, the enzyme respon-
sible for PAF synthesis in inflammatory conditions [19], was
upregulated 2.5 fold at the first day of lethal infection (Fig 1 G).
Quantification of protein in BALF may be used as a marker of
plasma leakage and, consequently, of lung injury [30]. There was
progressive protein accumulation in the airways after infection
with both inocula (Fig 1 C, F). Lung injury could also be observed
by histological evaluation in animals infected with Influenza A
(Fig 1 H, I). There was peribronchiolar and perivascular
infiltration at 10 days after infection with 104 PFU, but, as seen
by the normal thickness of alveoli, the infiltration was not present
in the majority of alveolar walls (Fig 1H). Inflammation appeared
to be more pronounced after infection with 106 PFU with
significant peribronchial, perivascular and perialveolar inflamma-
tion, with thickening of alveolar walls, edema and mucus
production on bronchioles at day 5 (Fig 1I).
There was a good correlation between the levels of CXCL1 and
CXCL2 in the lungs (Fig S1A, B and Fig S2A, B) and the
recruitment of neutrophils (Fig 1) after infection with 104 and 106
PFU. This is in agreement with studies showing the role of these
chemokines and their receptors for neutrophil recruitment during
Influenza A virus infection [31,32]. Levels of the chemokine CCL2
were increased above baseline from day 4 after infection with 104
PFU and from day 1 after 106 PFU (Fig S1C, S2C). Thereafter,
levels of CCL2 remained high throughout the observation period
after infection with the lethal inoculum. Levels of the pro-
inflammatory cytokine TNF-a were only increased at the
beginning of the infection, i.e. at days 1 and 4 after 104 PFU
and day 1 after 106 PFU (Fig S1D, S2D).
Decreased lethality rate and pulmonary injury in PAFR
deficient mice infected with Influenza A/WSN/33 H1N1
virus
Aiming to evaluate a possible role of the inflammatory mediator
PAF in Influenza A virus infection, PAFR and WT mice were
infected with 104 PFU or 106 PFU of Influenza A/WSN/33
H1N1 virus. Infection of WT mice with 104 PFU resulted in 35%
lethality rate. In contrast, only 7% of PAFR KO mice died after
infection with the same inoculum (Fig 2A). Inoculation of 106 PFU
caused 100% death by day 9 after infection of WT mice. In
contrast, 23% PAFR KO infected with 106 were alive at day 21
after infection (Fig 2A).
As the absence of PAFR resulted in partial protection from
Influenza A-associated lethality and in an attempt to seek for
mechanisms of protection, we evaluated several parameters of
inflammation in the lungs of mice after infection with 106 PFU.
Author Summary
Influenza virus causes disease that affects people from
different age, gender or social conditions. The illness
spreads easily and affects millions of people every year.
Vaccines are effective preventive approaches, but the high
degree of viral antigenic drift requires annual formulation.
Anti-viral drugs are used as therapy, but are only effective
at the very early stages of disease. The main symptoms
that lead to hospitalizations and deaths are associated
with the severe inflammatory host immune response
triggered by the virus infection. Our approach was to
decrease the inflammatory events associated with the viral
infection by targeting a molecule, Platelet Activating
Factor receptor (PAFR), known to induce several inflam-
matory events, including leukocyte recruitment and
leakage. We found that PAFR deficient mice or wild type
mice treated with a PAFR antagonist had less pulmonary
inflammation, pulmonary injury and lethality rates when
infected by two subtypes of Influenza A virus. In contrast,
the immune response against the virus, as assessed by viral
loads and specific antibodies, were not decreased. Our
findings concur with the idea that severe inflammation
plays an important role in flu morbidity and mortality and
show that PAFR is a major driver of the exacerbated
inflammation in mice infected with Influenza A virus.
Relevance of PAFR for Influenza A Injury
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After infection with 106 PFU, there was decreased recruitment of
total leukocytes (Fig 2B), mononuclear cells (Fig 2C) and
neutrophils (Fig 2D) in the airways of PAFR KO mice when
compared to WT mice. Neutrophil accumulation in lungs of WT
and PAFR KO infected mice was similar at the evaluated time
point (Fig 2E), as assessed by MPO quantification. The
concentration of Evans’ blue in BALF, a marker of vascular
permeability, was reduced by approximately 35% in PAFR KO
when compared to WT mice infected mice (Fig 2F). To examine in
greater detail pulmonary changes and inflammation induced by
infection with Influenza A, lung sections stained with H&E were
analyzed and graded by a pathologist blind to the experimental
Figure 1. Inflammatory profile following Influenza A/WSN/33 H1N1 infection. C57BL/6J mice were infected intranasally with Influenza A/
WSN/33 H1N1. Mice were killed (n = 6–8 in each group) 1, 4, 7 and 10 days after infection with 104 PFU and 1, 3 and 5 days after infection with 106
PFU. Relative number of neutrophils in lungs, as assessed by MPO assay, after infection with 104 PFU (A) and 106 PFU (D). Absolute numbers of BALF
neutrophils after infection with 104 PFU (B) and 106 PFU (E). BALF protein leakage after infection with 104 PFU (C) and 106 PFU (F). Relative mRNA
levels of LPAFAT/LPAFAT2 in lungs after infection with 106 PF assessed by Real Time PCR (G). Representative H&E stained slides at 1006 of
magnification of lungs of mice at 10 days after infection (dpi) with 104 PFU (H) and at 5 dpi with 106 PFU mice (I); bars represent 25mm. Histology
shows decreased inflammatory infiltrates and more preserved alveolar areas. Data are presented as Mean 6 SEM. *, ** and *** for p,0.05, p,0.01
and p,0.001, respectively, when compared to Mock or indicated groups (one-way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g001
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Figure 2. Lethal and mild Influenza A/WSN/33 H1N1 infections were less severe in PAFR KO deficient mice.WT and PAFR KO mice were
challenged intranasally with 104 (n = 17/16, two independent experiments) and 106 PFU (n = 22/30, two independent experiments) or PBS (Mock,
n = 4) and monitored for 21 days. Survival was greater in PAFR KO infected groups (A); * for p,0.05; log rank test. Total leukocyte (B), mononuclear
cell (C) and neutrophil (D) influx in the airways at 5 days after infection with 106 PFU Influenza A (two independent experiments). Numbers of lung
neutrophils, as assessed by MPO assay (E), after infection with 106 PFU of Influenza A (two independent experiments). Evans’ blue concentration in
BAL fluid (F) after infection with 106 PFU of Influenza A was assessed at 620nm and compared to a standard curve (one experiment). Data are
presented as Mean 6 SEM. *, ** and *** for p,0.05, p,0.01 and p,0.001, respectively, when compared to Mock groups; # for p,0.05 and ## for
p,0.01 when compared to WT infected group (one-way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g002
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situations. Leukocyte infiltration into bronchioles and alveoli,
hyperemia, exudation, edema and bronchial mucus production
were observed in most tissue sections from infected WT mice
(Fig 3E, F). Despite of similar myeloperoxidase levels (Fig 2E) and
neutrophilic infiltrates (Fig 3I) in lungs of infected groups, in PAFR
KO mice, cellular infiltrates were restricted to conducting airways,
in peribronchiolar and perivascular areas and did not reach distal
airways like alveoli and the lung parenchyma, where gas exchange
occurs (Fig 3G, H). Grading scores confirmed the limitation of
infiltrates around the airways, the vessels and showed that these
infiltrates were present in smaller areas of the parenchyma of
PAFR KO infected mice – ranging from 1 to 29% of affected
parenchyma in PAFR KO infected mice against 10 to 69% of
affected parenchyma in WT infected mice (p,0.05, Fig 3I). Thus,
the inflammatory infiltration in the larger airways was similar in
WT and PAFR KO mice infected with the lethal inoculum;
however, there was more infiltration of respiratory alveoli, with
thickening of alveolar walls and pneumonitis in lungs of WT mice.
Experiments in animals infected with 104 PFU showed decreased
neutrophil influx and less protein leakage, hence less pulmonary
injury, in PAFR KO mice when compared to WT infected mice
after 8 days of infection (data not shown). Pulmonary inflamma-
tion after 5 days of infection with 104 PFU was discrete and
restricted to neutrophil infiltration and compromised a percentage
of lung parenchyma between 10 and 29%, which is much less
severe than lesions developed after lethal infection. Pulmonary
inflammation in PAFR KO mice infected with the low inoculum
was also discrete and similar to that found in lungs of WT mice
(data not shown).
Because there was a significant change in the pathological score,
we conducted a more detailed analysis of leukocyte populations in
BALF and in lungs of infected mice. In the airways, there was an
increase in the number of all leukocyte populations evaluated at
day 5 after infection – CD4+ T cells, CD8+ T cells, NKT cells, NK
cells, macrophages and neutrophils. CD8+ and CD4+ lympho-
cytes, NK and NKT cells were equally increased in WT and
PAFR KO infected mice (data not shown). Number of
granulocytes (Fig 4A) and macrophages (Fig 4B) were increased
after infection of WT mice but this increase was lower in PAFR
KO mice infected with the same inoculum.
We performed Annexin V binding assay to evaluate whether
increased apoptosis could account for the decreased accumulation
of neutrophils and macrophages in the airways after flu infection of
PAFR KO mice. Influenza A induced a marked increase in the
number of apoptotic cells in the airways at day 5 after infection.
Overall, the number of apoptotic cells was greater in infected WT
than PAFR KO mice (Fig 4C). The number of apoptotic
granulocytes was similar in both infected groups (Fig 4D).
Therefore, the lower number of neutrophils in the airways of
PAFR KO infected mice was due to decreased recruitment of
these cells and not due to a higher degree of cellular death. In
contrast, there was decreased number of apoptotic macro-
phages and lymphocytes in infected PAFR KO than in WT mice
(Fig 4E, F).
Leukocyte populations were also evaluated in lung homoge-
nates. The percentage of lung CD3+CD8+ T cells did not increase
after infection (data not shown). CD3+CD4+ T cells increased
after infection in WT but not in PAFR KO mice (Fig 4G). F4-80+
CCR5+ (macrophage) and GR1+ CXCR2+ (neutrophils) cells in
lung homogenates increased after infection in both WT and PAFR
mice to a similar extent (data not shown). NK populations
(CD3+NK1.1+ and CD32 NK1.1+) enhanced after infection in
WT mice but the enhancement was significantly greater in PAFR
KO mice (Fig 4H, I, J).
Levels of cytokines and chemokines after Influenza A
virus infection in WT and PAFR KO mice
The concentrations of the cytokines IL-1b, IL-6, TNF-a,
CXCL1, CXCL2, CCL5, IFN-c and IL-12p40 were evaluated
in lung homogenates of control and Influenza infected mice. As
seen in Figure S2, levels of TNF-a and CXCL2 were not
increased in the lungs at day 5 after infection with 106 PFU
infection in both WT and PAFR KO groups (data not shown).
Levels of IL-6 (Fig 5A) and CXCL1 (Fig 5B) were increased
after infection but there was no difference between WT and
PAFR KO mice. Levels of IL-1b were also enhanced by
infection but the increase was more pronounced in PAFR KO
than WT infected mice (Fig 5C). Levels of IL-12p40 (Fig 5D),
IFN-c (Fig 5E) and CCL5 (Fig 5F) increased after infection and
the increase was more pronounced on WT that PAFR KO
mice.
PAFR deficiency did not impair the ability of the immune
system to deal with Influenza A/WSN/33 virus
Because pulmonary inflammation and levels of some cytokines
known to be important for host resistance to viral infection,
including IFN-c and IL-12p40, were decreased in PAFR KO
mice, we investigated whether this reduction was sufficient to
impair viral clearance and adaptive responses. As seen in
Figure 6A, there was no difference in viral load at day 5 in the
lungs of WT and PAFR KO mice infected with 106 PFU (Fig 6A)
or 104 PFU (Fig 6B). In animals infected with 104 PFU, viral load
was significantly lower in PAFR KO than WT mice at day 8 after
infection (Fig 6C).
Next we investigated humoral adaptive immune responses in
the presence or the absence of PAFR. In a re-infection protocol,
animals were initially infected with a non-lethal (103 PFU)
inoculum of Influenza A/WSN/33 H1N1. After 14 days, animals
were subjected to another infection with the same virus, at this
time using the lethal inoculum, 106 PFU. No weight loss or
lethality was observed in WT or PAFR KO mice using this
protocol (data not shown). Measurement of anti-Influenza A
WSN/33 IgG revealed no differences in antibody titer between
the groups at day 21 after re-infection. The titer was 1/250 in both
groups and the optical densities at that dilution are shown in
Fig 6D.
Normal virus propagation in epithelial cells
Because there was decreased survival and pulmonary
inflammation in PAFR-deficient mice and this was associated
with decreased viral load after infection with the lower inoculum
at day 8 after infection, we assessed whether virus propagation
was altered by the absence of PAFR. To this end, we infected
A549 cell line, a human alveolar basal epithelial cell, with
Influenza A virus expressing red fluorescent protein (RFP).
Using this methodology, we found no difference in the ability of
influenza virus to infect epithelial cells in vitro in the absence or
presence of a PAFR antagonist PCA 4248 (50 mM) (data not
shown).
We also measured the height of bronchiolar epithelium after
infection with 106 PFU to determine whether infection of epithelial
cells, the primary target of influenza infection, was similar in the
absence or presence of PAFR. Lethal infection promoted
pronounced reduction in epithelial height of bronchiole and
absence of PAFR did not alter the susceptibility of epithelial injury
(Fig S3). Therefore, virus entry and replication and subsequent cell
injury in its primary target, epithelial cells, is not affected when
PAFR is absent.
Relevance of PAFR for Influenza A Injury
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Activation of TLR7/8 but not TLR3 and NLRP3 was
dependent of PAFR
TLR3, TLR7/8 and NALP3 are thought to be major
intracellular recognition molecules used by the host to detect
Influenza A infection [14]. To investigate whether these activation
of these pathways could lead to inflammation in a PAFR-
dependent manner, we studied the effects of synthetic agonists of
TLR7/8 (R848) and TLR3 and NLRP3 [poly(I:C)] in WT and
PAFR KO mice.
Intratracheal instillation of R848, a TLR7/8 agonist, induced
LPAFAT/LPAFAT2 mRNA in lungs of WT mice (Fig 7A). This
was accompanied by infiltration of neutrophils in lungs (Fig 7B)
and airways (Fig 7C), and increased levels of IL-12p40 (Fig 7D),
IL-6 (Fig 7E) and CXCL1 (Fig 7F) in lungs of WT mice. In PAFR
KO mice, R848 induced similar amount of neutrophil influx in
lungs (Fig 7B), but greatly reduced neutrophil recruitment to the
airways (Fig 7C). Levels of IL-12p40 (Fig 7D) and CXCL1 (Fig 7F)
were reduced in lungs of PAFR-KO mice instilled with R848
when compared to WT.
Poly(I:C) stimulation did not induce expression of LPAFAT/
LPAFAT2 mRNA in WT mice (Fig S4A). Instillation of poly(I:C)
induced neutrophil influx in the airways (Fig S4C), but not lungs
(Fig S4B) and CXCL1 production in lungs (Fig S4D) of WT mice,
a response that was similar or slightly greater in PAFR KO mice.
Treatment with a PAFR antagonist protected against
Influenza A/WSN/33 H1N1 infection
To test the potential use of PAFR as a pharmacological target
against Influenza A-associated disease, we used the selective PAFR
antagonist PCA 4248 in a therapeutic protocol. The treatment was
started 3 days after infection of mice with 104 or 106 PFU and was
continued until day 10. Day 3 was chosen because this is the time
at which weight loss and neutrophil influx peaked in the higher
inoculum (Fig 1B, G). Treatment with PCA 4248 significantly
enhanced survival after infection with 106 PFU of Influenza A/
WSN/33 H1N1 virus (Fig 8A). Akin to the experiments in PAFR
KO mice, higher survival was accompanied by reduction in total
leukocyte (Fig 8B), mononuclear cells (Fig 8C) and neutrophil
(Fig 8D) accumulation in the airways. Neutrophilic accumulation
in lung parenchyma after Influenza infection was not affected by
PCA 4248 treatment (Fig 8E) as observed in PAFR KO (Fig. 2E).
Plasma leakage in the airways, as assessed by measuring total
protein in BAL was significantly lower in PCA 4248-treated than
vehicle-treated animals (Fig 8F).
PCA treatment failed to alter significantly (from 55% to 90%
survival, p = 0.10) the lethality rate caused by 104 PFU infection
(Fig 8A), but there was a significant decrease in weight loss from
the ninth to the eleventh day of infection, when compared to the
vehicle-treated group (Table 1).
PAFR deficient mice were protected from infection
caused by another subtype - Influenza A H3N1
To assess whether the protection observed in PAFR deficient
mice and WT mice treated with a PAFR antagonist infected with
Influenza A H1N1 was virus-specific, we used another virus strain,
a reassortant Influenza A H3N1 subtype to infect WT and PAFR
KO mice. Since mouse infection with different Influenza virus
subtypes requires adaptation [33], H3N1 virus was subjected to
three lung passages in C57BL/6J in order to cause disease in these
animals. After three lung passages the virus was able to multiply
and increased viral titer (data not shown), a sign of adaptation. As
a result, the inoculum of 106 PFU of H3N1 virus was enough to
cause 15% of weight loss on average after three days of infection.
PAFR KO mice were protected from the disease caused by
Influenza A H3N1, since they start to regain weight, from day ten
of infection, faster than WT animals (Fig 9).
Discussion
Severe inflammation caused by highly pathogenic Influenza A
strains was described to be an important cause of death during
1918 pandemics and highly pathogenic avian Influenza H5N1
infections [34]. Using a mouse-adapted Influenza A/WSN/33
H1N1 strain we show a correlation between viral load,
pathogenesis and lethality – i.e. the higher the viral load, there
is greater lung injury and death. More importantly, the present
work demonstrates that the course of Influenza A virus infection is
less severe in the absence of PAFR. Mechanistically, it appears that
activation of TLR7/8 by Influenza A explains the induction of
LPAFAT/LPAFAT2 mRNA and consequent activation of PAFR.
Further, absence or blockade of PAFR during infection is
associated with decreased neutrophil and macrophage influx into
airspaces, decreased production of certain pro-inflammatory
mediators and decreased lung edema, parameters which are
commonly increased after pulmonary administration of PAF to
rodents or humans [35,36]. Lack of PAFR did not increase viral
load or prevent specific anti-Influenza antibody production.
Finally, we demonstrate that administration of PAFR antagonist
3 days after infection also causes similar protection as observed in
PAFR-deficient mice.
Neutrophils and neutrophil-active chemokines peaked very
early in the course of Influenza A/WSN/33 H1N1 infection and
decreased thereafter. On the contrary, lung edema and injury was
progressive. Thus, it seems that inflammation is self-resolving but
causes lung damage which is more pronounced in the last days of
infection, leading to progressive weight loss and death. As
inflammation is important to trigger lung injury in Influenza A
infected mice and PAF attracts neutrophils into the lung [36], we
evaluated whether the receptor for PAF was involved in H1N1-
associated lung inflammation and injury, and death. A previous
study demonstrated up-regulation of PAFR mRNA in lungs
following Influenza A/PR8/34 H1N1 infection [29]. This is
consistent with the expression of PAFR on neutrophils and other
leukocytes [20] and the influx of these cell types during infection.
In our experiments, we found increased expression of the enzyme
involved in inflammatory synthesis of PAF – LPAFAT/LPAFAT2
– in the first day of lethal infection. Therefore, the release of PAF is
an early event that could be involved in the pathogenesis of
Influenza A infection. In fact, PAFR deficient mice or mice treated
Figure 3. Histological changes after Influenza A WSN/33 H1N1 lethal infection in WT and PAFR deficient mice. Representative lung
slides of WT mock (A, B), PAFR KO mock (C, D), WT (E, F) and PAFR deficient mice (G, H) infected with 106 PFU, after five days of infection. Perialveolar
infiltration, vascular and parenchyma inflammation induced by Influenza A virus infection are reduced in PAFR KO mice. Pictures on the left (A, C, E, G)
were taken under 1006magnification, bars represent 25mm. Pictures on the right (B, D, F, H) were taken under 4006magnification in the areas
highlighted in the lower magnification, bars represent 10mm. Bronchiole and vessels are indicated with ‘‘b’’ and ‘‘v’’, respectively. Histopathological
score (maximal of 18) evaluated airway, vascular, parenchymal inflammation, neutrophilic infiltration (I). Data are presented as Mean 6 SEM. ** and
*** for p,0.01 and p,0.001, respectively, compared to Mock groups; # for p,0.05 and ## for p,0.01 compared to WT infected group (one-way
ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g003
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with PAFR antagonist PCA 4248 were protected from death or
weight loss caused by Influenza A virus infection. PAFR signaling
was also important for pulmonary inflammation and injury.
Neutrophils are required for the clearance of Influenza virus
during the early stages of infection [37]. The antiviral actions of
neutrophils are clearly demonstrated through the use of RB6-8C5
antibodies to deplete these cells. In the absence of neutrophils,
mice are more susceptible to virus growth and associated lethality
[15,38]. Therefore, direct ablation of neutrophils cannot be used
therapeutically. On the other hand, Influenza A virus is known to
be a potent activator of neutrophil respiratory burst, apoptosis and
subsequent deactivation in front of a second stimulus [16]. The
Figure 4. Leukocyte populations in lungs following Influenza A/WSN/33 H1N1 infection of WT and PAFR deficient mice.WT and PAFR
KO mice were infected intranasally with 106 PFU of Influenza A virus (n = 5/6) or PBS (n = 4) and killed after 5 days. Airway leukocytes recovered by BAL
were stained with specific antibodies and evaluated by flow cytometry, according to size and granularity (A, B). Number of neutrophils GR1+ CXCR2+
(A) and macrophages F4/80+ CCR5+ (B) found in BALF. BALF cells were also stained with Annexin V (AnV) and Propidium iodide (PI) to assess
apoptosis. Number of apoptotic BALF leukocytes (C), granulocytes (D), macrophages (E) and total lymphocytes (F) according to size, granularity, AnV
staining and absence of PI incorporation. Leukocytes recovered from lung homogenates were also subjected to flow cytometric analysis. CD4
lymphocytes, CD3+ CD4+ (G), NKT cells, NK1.1+CD3+ (H) and NK cells, NK1.1+CD32 (I) were expressed as percentages of total leukocytes.
Representative dot plots of NK1.1 and CD3 expression on lymphocytes gate (J). Data are presented as Mean 6 SEM. *, ** and *** for p,0.05, p,0.01
and p,0.001, respectively, compared to Mock groups; # for p,0.05, ## for p,0.01, and ### for p,0.001, compared to WT infected group (one-
way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g004
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neutrophil activation that occurs during infection, despite its role
in controlling viral replication, is thought to be very harmful to the
host [37]. PAFR deficiency or antagonism increased survival after
Influenza A virus infection and this was associated with lower
neutrophil recruitment to the airways. There was, however, no
inhibition of neutrophil into pulmonary parenchyma. Therefore,
reduction instead of ablation of neutrophil recruitment into the
airways appears to be an approach which is sufficient to maintain
control of viral burden, but, at the same time, avoid excessive
neutrophil activation and lung damage.
Bacterial pneumonia, especially by Streptococcus pneumonia, is an
important complication following Influenza A virus infection [39].
Pro-apoptotic effects of Influenza A virus on neutrophils are one of
the explanations for the increased susceptibility to bacterial
pneumonia after Influenza infection [40]. In our model, absence
of PAFR did not influence neutrophil apoptosis. The role of PAFR
Figure 5. Cytokines and chemokines in lungs following Influenza A/WSN/33 H1N1 infection of WT and PAFR-deficient mice. WT and
PAFR KO mice were infected intranasally with 106 PFU (n = 5–9) or PBS (Mock, n = 4) and killed 5 days post infection. Pulmonary concentrations of IL-6
(A), CXCL1/KC (B), IL-1b (C), IL-12 p40 (D), IFN-c (E) and CCL5/RANTES (F) were measured by ELISA in lung homogenates. Data are presented as Mean
6 SEM. *, ** and *** for p,0.05, p,0.01 and p,0.001, respectively, compared to Mock groups;# for p,0.05,## for p,0.01 and### for p,0.001
when compared to WT infected group (one-way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g005
Figure 6. Viral load and specific antibodies after Influenza A/WSN/33 H1N1 infections of WT and PAFR-deficient mice. WT and PAFR
KO mice were infected intranasally with 106 PFU (n = 4–6) and killed 5 days post infection (A) or infected with 104 PFU (n = 4–6) and killed 5 (B) and 8
days post infection (C). Viral titers in lungs homogenates, as assessed by MDCK plaque formation. WT and PAFR KO mice (n = 4–6) were infected
intranasally with 103 PFU and after 14 days were reinfected with 106 PFU. After 21 days mice were killed and anti-Influenza A/WSN/33 H1N1 IgG titer
was measured in serum samples by ELISA (D). Data are presented as Mean 6 SEM. ** for p,0.01 when compared to WT infected group (unpaired t
test).
doi:10.1371/journal.ppat.1001171.g006
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in altering bacterial pneumonia after Influenza infection is
controversial. While the study of van der Sluijs and co-workers
described protection in PAFR KO mice after Streptococcus
pneumoniae following flu infection [29], McCullers and colleagues
showed no correlation between the increased pathology after
secondary infection and the antagonism [41] or absence of PAFR
[42]. Both groups focused on lethality and harm caused by the
bacteria, not the virus, and the overall message was that absence or
blockade of PAFR was either without effect or protective, but
never harmful. Here, we show that targeting PAFR during
Influenza A virus infection is protective against viral-induced
pneumonia, regardless of the risk of bacterial pneumonia after
viral infection.
In addition to neutrophils, endothelial cells express PAFR and
are affected by PAFR signaling [22]. Protein leakage to the
airways reflects the increased vascular permeability following
inflammatory events associated with Influenza A virus infection
[30]. In our system, lower protein amounts or Evans’ blue
extravasation were found in BALF of PCA treated or PAFR KO
animals. As mentioned above, neutrophil accumulation in the
parenchyma was not affected by PAFR absence or antagonism.
Thus, neutrophil transmigration into the alveolar space seems to
play an important role in the pathogenesis of Influenza infection.
During the transmigration, neutrophils may release proteinases or
oxygen reactive species that lead to increase in vascular
permeability that is accompanied by significant protein leakage
[43]. Hence, lower protein amounts found in lethally infected mice
treated with PCA or PAFR KO mice infected with lower infection
inoculum compared with their controls corroborates with this
hypothesis.
Pulmonary inflammation and injury are common histopatho-
logical findings in humans with mild or severe Influenza A
infection. Viruses of low pathogenicity affect basically the proximal
airways (bronchi and bronchioles), whereas highly pathogenic
viruses or infection of immunocompromised people infected is
associated with inflammation and injury in the distal airways
(alveoli and parenchyma). When distal airways are affected, lung
injury is more severe and lead to loss of respiratory capacity and
gas exchange [44]. In our system, the extent of distal airways
involvement was decreased in PAFR KO mice, suggesting these
results may bear relevance to humans with severe Influenza A
infection. Evaluation of gas exchange in our mice was not possible
as animals needed to be anesthetized for the procedure (data not
shown).
NK cells are recruited to the lungs very early in the course of
Influenza infection, are involved in initial viral clearance and
provide initial signals to the development of protective adaptive
responses [45]. NK cells recognize Influenza A virus through its
NKp46 receptor and, stimulated by IL-12 released from dendritic
cells, mediate cytotoxicity to infected cells and release of IFN-c
Figure 7. Inflammatory changes induced by R848 are PAFR dependent. WT and PAFR KO mice were instilled intratracheally with 50 mg of
R848 and killed after 4 hours. Relative mRNA levels of LPAFAT/LPAFAT2 in lungs of PBS or R848 instilled WT mice assessed by Real Time PCR (A).
Number of lung neutrophils, as assessed by MPO assay (B), neutrophil influx to the airways (C) after R848 instillation in WT and PAFR KO mice. Lung
levels of IL-12p40 (D), IL-6 (E) and CXCL1 (F) of WT and PAFR KO mice instilled with PBS or R848 were assessed by ELISA. Data are presented as Mean
6 SEM of 5–9 animals. *, ** and *** for p,0.05, p,0.01 and p,0.001, respectively, when compared to Mock groups; ## for p,0.01, and ### for
p,0.001, compared to WT instilled with R848 (one-way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g007
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that, in turn, mediates adaptive responses [46]. PAF seems to be
important for cytotoxic functions of NK cells [47,48] and PAFR
antagonists reduced cytotoxic activity of NK cells [47]. Jin and
colleagues showed that inflammation-released PAF recruits NK
cells activated by IL-2, IL-12, IL-15 and IFN-a [48]. Despite these
studies showing a potential effect of PAF on NK cell function and
recruitment, we actually observed that NK cell recruitment to the
lungs following Influenza A virus infection was increased in the
Figure 8. Treatment with a PAFR antagonist confers protection to mice infected with Influenza A/WSN/33 H1N1. In (A), WT mice were
infected intranasally with 106 PFU and 104 PFU and treated twice a day, from day three to ten post infection, with vehicle or the PAFR antagonist, PCA
4248 (5 mg/kg/dose). Survival was monitored daily and was improved in PCA-treated mice infected with 106 PFU, when compared to vehicle group
(A); (* for p = 0.0161; log rank test, n = 8–9). To assess lung responses, mice were treated twice a day, from day three to 5 post infection, with vehicle
or the PAFR antagonist, PCA 4248 (5 mg/kg/dose). Total leukocyte (B), mononuclear cell (C), and neutrophils (D) recruitment in the airways, as
assessed by counts of BALF recovered cells, are shown in Mock infected and 106 PFU infected, vehicle or PCA treated groups (n = 4–6, each group).
Neutrophil recruitment in the lung parenchyma, as assessed by MPO (E) and total protein quantification (F) in BALF (n = 6–8, each group) are also
shown. Data are presented as Mean 6 SEM. *, ** and *** for p,0.05, p,0.01 and p,0.001, respectively, when compared to Mock group; ## for
p,0.01 and ### for p,0.001 when compared to vehicle group (one-way ANOVA, Newman-Keuls).
doi:10.1371/journal.ppat.1001171.g008
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absence of PAFR. Our studies do not provide a mechanism to this
particular finding but do suggest that enhanced NK cell
recruitment could be functionally relevant as seen by lower viral
loads in the lung in some of the experiments.
In the absence of PAFR, there were reduced pulmonary levels
of IFN-c, IL-12p40 and CCL5. The reduction in these cytokines
which are preferentially produced by or activate Th1 lymphocytes
is related to the reduced number of CD4+ T cells in the lungs of
PAFR-deficient mice infected with influenza A. These results are
consistent with previous experiments in mice infected with a
different microorganism, Leishmania amazonensis, where we also
demonstrated that absence of PAFR decreased CCL5 expression
and Th1-associated function [49]. However, in the case of the
protozoan infection, the absence of PAFR was deleterious, because
of an inability of the host to control the infection [49]. These
results suggest that PAF may be important regulator of CCL5
production and consequent infiltration of effectors T cells with
Th1 phenotype in vivo. Despite decreased IFN-c expression and
decreased accumulation of CD4+ T cells in the lungs of infected
PAFR-deficient mice, viral load in the lung was decreased or at
worst similar to that found in WT mice. Reduction of viral load
was not associated with decreased propagation in epithelial cells in
vitro. Furthermore, the capacity of Influenza virus to cause
epithelial cell injury in vivo was unchanged by absence of PAFR.
It is unclear why there was a small decrease in viral load in the
lungs on day 8 after infection with the low inoculum. It is possible
that this may reflect the better clinical status of animals and the
decreased pulmonary inflammation in the absence of PAFR.
Absence of PAFR was not associated with a decreased specific
antibody release, as shown by re-infection studies and measure-
ment of specific IgG titers. Therefore, changes in CD4+ T cell
recruitment and related cytokines were not sufficient to modify
negatively the course of infection in this model of experimental
Influenza A virus infection.
Macrophages are also recruited to the lungs and airways after
Influenza infection where they are thought to play an important
role in the production of pro-inflammatory cytokines and in the
phagocytosis of Influenza virus-induced apoptotic cells [50]. In
vivo abrogation of phagocytosis of apoptotic infected cells by
macrophages increases lethality rates in Influenza A infected mice
[51]. We found a partial reduction of macrophage recruitment to
the airways in PAFR deficient mice infected with Influenza A.
There was also, a proportional reduction in number of apoptotic
macrophages in PAFR deficient mice, showing that the proportion
of live active macrophages was similar in both groups. These
macrophages appear to be sufficient for clearance of apoptotic
infected cells and helping in the resolution of the inflammatory
phase of the infection [52], as seen by the reduced lung damage
and survival in infected PAFR-deficient mice.
The suggestion that macrophage function in infected PAFR-
deficient mice was sufficient to keep immune responsiveness is
strengthened by findings that IL-6 expression was maintained and
IL-1b expression was actually increased in these mice. IL-1b is
produced mainly by macrophages after infection with Influenza A
[13]. The role of IL-1b for viral clearance and pathology during
Influenza infection is very complex [53]. Indeed, a previous study
has shown that IL-1R1 deficient mice had greater lethality rates,
but decreased lung damage caused by Influenza A virus infection
[53]. Maines and colleagues showed a clear inverse correlation
between viral virulence and IL-1b release in lungs [54]. While
highly virulent H5N1 virus induces a small increase in IL-1b
secretion, low virulent H5N1 stimulates high levels of this cytokine
[54]. Therefore, the cytokine IL-1b does appear to contribute to
viral clearance, even at the cost of increasing pulmonary
recruitment of leukocytes in some models. In our system,
enhanced release of IL-1b in PAFR-deficient mice was associated
with maintained or decreased viral load, but no enhancement of
leukocyte infiltration or pathology. The inability of IL-1b to
enhance inflammation in the system may be explained by the role
of PAFR in mediating IL-1b-associated inflammation [55,56].
Table 1. Body weight changes after Influenza A/WSN/33
H1N1 infection in mice treated with vehicle or PCA4246.
Day after 104
PFU infection
Vehicle (% of
starting weight)
PCA 4248 (% of starting
weight)
3A 94.662.5 – n = 8 94.660.9 (p = 0.9921) – n= 8
9 75.861.9 84.262.6 (* p = 0.0263)
10B 74.862.6 87.463.2 (* p = 0.0104)
11 75.563.6 87.363.8 (* p = 0.0495)
21C 88.965.6 – n = 4 96.161.6 (p = 0.1511) – n= 7
A– First day of PCA 4248 treatment;
B– Last day of PCA 4248 treatment;
C– Last day of experiment;
*for p,0.05. Starting and finishing experimental numbers are indicated.
doi:10.1371/journal.ppat.1001171.t001
Figure 9. Weight loss after Influenza A (equine/Cordoba/18/1985 - Yamagata/32/1989) H3N1 infection of WT and PAFR-deficient
mice.WT (n= 5) and PAFR KO (n= 6) mice were infected with intranasally 106 PFU Influenza A H3N1 virus and weight monitored daily. PAFR-deficient
mice lost significantly less weight at days 10, 11, 13 and 14 days after when compared to WT mice. Data are presented as Mean 6 SEM. * for p,0.05.
Unpaired t test.
doi:10.1371/journal.ppat.1001171.g009
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The recognition of Influenza virus RNA is the main trigger of
antiviral and inflammatory responses [14]. Using the synthetic
TLR agonist R848, we found that activation of this ssRNA sensor
induces the expression of LPAFAT/LPAFAT2 and inflammation
that is directly dependent of PAFR. It has been previously shown
that LPAFAT/LPAFAT2 expression and enzyme activity may be
induced by the TLR9 ligand ODN1826 and the TLR4 ligand
LPS [19]. Poly(I:C), a classical TLR3 ligand and recently
described as a NLRP3 activator [10], did not induce LPAFAT/
LPAFAT2 mRNA expression and cause pulmonary inflammation
which was PAFR-independent. Therefore, of the known major
recognition receptors for Influenza, it appears that TLR7/8 is the
one capable of inducing LPAFAT/LPAFAT2 expression and
triggers pulmonary inflammation in PAFR-dependent manner.
Results with R848 were qualitatively similar (LPAFAT/LPA-
FAT2 mRNA expression, PAFR-dependency of inflammation) to
that observed after Influenza infection, suggesting that activation
of TLR7/8 is a main mechanism by which Influenza infec-
tion leads PAF release and PAFR activation. One alternative
possibility to explain the activation of PAFR in our system derives
from recent findings that oxidized phospholipids (Ox-PL) were
produced during acute lung injury induced by inactivated H5N1
[27]. Ox-PL are PAF-like molecules known to induce PMN
migration and protein leakage in pleural cavity, effects which are
PAFR-dependent [57]. Ox-PLs levels were also correlated with
the reduced severity of flu in IL-17RA KO mice infected with
Influenza A/PR/8/34 (H1N1) [28]. Thus, production of Ox-PL
may contribute to the activation of PAFR during influenza
infection.
The present model of Influenza A/WSN/33 H1N1 infection
mimics infections with highly pathogenic strains during pandemics
or in immunocompromised people. We used a low inoculum of
H1N1 and a low pathogenic Influenza A strain to model the
common features of the seasonal flu in humans. Using a low
pathogenic Influenza A H3N1 reassortant virus, we showed that
PAFR deficient mice had decreased weight loss in comparison to
WT mice. Therefore, PAF may be important to the pathogenesis
of Influenza A virus infection, regardless of subtype or strain. This
feature could be explained because PAFR targeting modulates the
inflammatory response to the virus, without affecting, or also
improving viral clearance by the host. Recently, our group
published similar results in a murine model of Dengue virus
infection. In that work, the absence or pharmacological blockade
of PAFR resulted in protection against the main symptoms of
dengue virus infection and lethality, regardless of viral titer change
[58].
In conclusion, our studies clearly show that PAFR-mediated
inflammatory events that follow Influenza A virus infection are
important for disease pathogenesis and lethality. Mechanistical-
ly, protection in PAFR deficient mice was associated with
decreased infiltration of neutrophils and macrophages into the
airways and decreased lung damage. Importantly, PAFR
deficiency tended to enhance the ability of the murine host to
deal with the virus and antibody and adaptive response were
maintained. Importantly, treatment with PAFR antagonists
starting 3 days after infection also protected against Influenza
A morbidity and lethality. These studies show that PAFR is a
disease-associated gene after Influenza A virus infection and
suggest that PAFR antagonism could be a useful therapeutic
target to interfere with inflammatory damage that follows
infection. It remains to be determined whether this will be a
useful therapeutic strategy in humans and whether association
with antiviral will enhance benefits provided by each individual
strategy, as suggested elsewhere [59].
Methods
Ethics statement
All the experiments were conducted under prior CETEA/
UFMG animal ethics committee approval (203/08), according to
Brazilian guidelines on animal work.
Virus strains and culture
The strains used in the study were Influenza A WSN/33 H1N1
and Influenza A (H3 of equine/Cordoba/18/1985 and N1 of
Yamagata/32/1989) H3N1. Briefly, Influenza A WSN/33 H1N1
was produced in chicken eggs and passed once more in eggs and
then cultured in MDCK (Madin-Darby Canine Kidney) cells. The
stocks in a final concentration between 46107 and 26108 PFU/
mL were diluted in sterile phosphate buffered saline prior to
infections.
Influenza A H3N1 strain was adapted to mice through three
lung passages. Briefly, 104 PFU of Influenza A H3N1virus was
inoculated via intranasal in five animals and after 5 days lungs
were collected an tittered. The sample that had the higher titer
(105 PFU) was passed through a 0.45 mm filter and used to infect
another 5 animals (100 PFU/animal). The process of selection was
repeated once and the final titer achieved was 56107 PFU. The
stock was diluted in sterile phosphate buffered saline prior to
infections.
Animal infections
Male 8–10 weeks C57BL/6J and PAFR deficient mice (PAFR
KO) on a C57BL/6J background, maintained in pathogen free
conditions at Laboratorio de Imunofarmacologia (UFMG/Brazil)
facilities, were used in the infection experiments. Mice anesthe-
tized with ketamine/xylazine received 25mL of Influenza A/
WSN/33 H1N1 virus, Influenza A H3N1virus, or sterile
phosphate buffered saline (PBS, Mock group), intranasally. The
H3N1 virus was previously adapted to mice, through three lung
passages as described above.
Drug treatment
The PAFR antagonist PCA 4248 (Tocris Bioscience), 5mg/kg,
diluted in 5% of ethanol in PBS was given twice a day, via
subcutaneous injections. The control group (vehicle) received the
same volume of the solution used to dilute PCA 4248.
In vitro infections
MDCK and the human lung epithelial cell line A549 (ATCC
CCL-185) were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 6% of fetal bovine serum were
cultured at 37uC with 5% of CO2. Cells were seeded at a density
of 46104 cells/well in a 24-well plate and after 24 hours of growth
were incubated with 50 mM of PCA 4248 in DMEM or vehicle for
30 minutes. Cells were infected with a multiplicity of infection of 2
with a red fluorescent protein (RFP) labeled Influenza A virus and
incubated for 16 hours. Virus propagation was observed through a
fluorescence microscopy.
Experimental design
Influenza A infection. Wild Type (WT) mice were infected
with distinct Influenza A/WSN/33 H1N1 inocula. PAFR KO and
WT mice, PCA 4248 or vehicle treated were infected with lethal
(106 PFU) and lower infection (104 PFU) inocula. Mice were
monitored by weight loss and lethality for 21 days or sacrificed
after indicated days of infection to have cellular recruitment to the
airways and to the lungs evaluated, as well as cytokine and
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chemokine production, and lung injury and viral load assessment.
Animals which lost more than 30% of their initial weight were
killed; however, the maximum weight loss observed was lower
than 30%. LysoPAFAT/LPCAT2 gene expression was assessed in
lungs of WT mice infected with the lethal inoculum. WT and
PAFR KO mice were infected with the non-lethal inoculum of 103
PFU of Influenza A/WSN/33 H1N1, monitored for 14 days and
reinfected with the lethal inoculum of the same virus. After 21
days, reinfected mice were killed and serum samples were used to
measure specific IgG titers. Finally, WT and PAFR KO mice were
infected with Influenza A (equine/Cordoba/18/1985 - Yamagata/
32/1989) H3N1 and monitored for 21 days.
TLR7/8, TLR3 and NLRP3 activation. Anesthetized WT
and PAFR KO mice were instilled intratracheally with 40mL
containing a sterile PBS with 50 mg of R848 or poly(I:C)
(Invivogen, San Diego, USA), or saline only (controls) and killed
at 4 (R848) or 8 [poly(I:C)] h after instillation. Lungs were washed
and removed for evaluation of cell, MPO levels, and cytokine and
chemokine production. The lower lobe of the left lung of WT
animals was excised for the evaluation of LysoPAFAT/LPCAT2
gene expression by Real Time PCR.
Bronchoalveolar lavage (BAL)
At indicated time points, mice were euthanized with an
overdose of ketamine/xylazine solution. Subsequently, a 1.7mm
catheter was inserted into the trachea and two 1mL aliquots of
PBS were inserted into the lungs and collected three times to
acquire leukocytes recruited to the airway space. After centrifu-
gation, the pellet was used to total and differential leukocytes
counts of stained slides.
Assessment of pulmonary vascular leakage by Evans blue
At day 5 after infection with 106 PFU of Influenza A WSN/33
or PBS instillation, WT and PAFR were injected with Evans blue
dye (50 mg/kg, i.v.) 2 h before they were killed. Animals were
subjected to BAL with 1mL of PBS. BALF was then centrifuged
and the optical density was determined at 620 nm. The
concentration of extravasated EBD (microgram of EBD per gram
lung) in lung homogenates was calculated against a standard
curve.
Lung myeloperoxidase measurement
After performing BAL, lungs were perfused with 5 mL of PBS
to remove circulating blood and frozen. A hundred ml of tissue was
homogenized to perform ELISA and MPO assay, as previously
described [60].
Measurement of cytokines and chemokines
Lung tissues were homogenized in a PBS-buffer containing
antiproteases, as previously described [60], to assess the concen-
trations of the cytokines IL-1b, IL-6, IL-12 p40, IFN-c and TNF-a
and the chemokines CXCL1, CXCL2, CCL2, CCL5 and serum
IL-6 levels by ELISA DuoSet kits (R&D Systems), in accordance
to the manufacturer’s instructions.
Real time PCR
Total RNA from diaphragmatic lung lobe tissue conserved at
270uC in RNA later (Applied Biosystems, California, USA) was
extracted using Trizol (Invitrogen), as described by the manufac-
turer. The total RNA obtained was suspended in RNAse-free
water and stocked at 270uC. Real-time PCR was performed on
an ABI PRISM Step-One sequence-detection system (Applied
Biosystems) by using SYBR Green PCR Master Mix (Applied
Biosystems) after a reverse transcription reaction of 2 mg of RNA
by using M-MLV reverse transcriptase (Promega). The relative
expression level of LysoPAFAT/LPCAT2 gene was determined
by the 2 (2delta delta Ct) method, normalized by ribosomal
subunit 18S and expressed as fold change compared with
constitutive gene expression. The following primer pairs were
used: LysoPAFAT/LPCAT2 forward 59 GTCCAGCAGACTAC-
GATCAGTG 39; LysoPAFAT/LPCAT2 reverse 59 CTTATTG-
GATGGGTCAGCTTTTC 39 as described by [19]; and 18S
forward 59 CTCAACACGGGAAACCTCAC 39; 18S reverse 59
CGTTCCACCAACTAAGAACG 39.
Assessment of lung injury and histological analysis
We analyzed lung injury following Influenza A virus infection
assessing protein leakage to the airways, histological changes in
lung architecture. A protein quantification assay (Bio-Rad
Protein Assay) was performed in bronchoalveolar lavage fluid
(BALF) supernatant according to manufacturer’s instructions.
Formalin-fixed lung left lobes were dehydrated gradually in
ethanol, embedded in paraffin, cut into 4-mm sections, stained
with H&E and examined under light microscopy and scored by a
pathologist blinded to the experiment. The score of 18 points
was based on Horvat and colleagues paper [61], which evaluates
airway, vascular and parenchymal inflammation, added to a
5 points score evaluating general neutrophilic infiltration (0,
absent; 1, minimal; 2, slight; 3, moderate; 4, marked; and 5,
severe).
Photographs of areas containing bronchioles in H&E stained
slides were taken under 200 fold of magnification and were
analyzed with an AxioVision software. Epithelial height of
bronchioles in areas of inflammatory infiltrates had their length
measured. The number of bronchioles analyzed in each slide
varied according to their length, to totalize 1500 mm per slide. The
mean epithelial height for each animal was used to construct the
graph.
Flow-cytometric analysis of lung and airway leukocyte
populations
Leukocytes recovered from BALF and from lungs processed
with collagenase IV (Sigma) [62] were stained with fluorescent-
labeled monoclonal antibodies CD3, CD4, CD8, NK1.1 and GR1
(BD Pharmigen TM); CXCR2 (R&D Systems); F4/80 and CCR5
(Biolegend). Stained cells were acquired in FACScan cytometer
and analyzed in FlowJo (Tree Star) software (Text S1).
Apoptosis assay
We performed Annexin V binding assay on BALF leukocytes
using Annexin V/Propidium Iodide (PI) kit (Caltag Laboratories)
according to manufacturer’s instructions. Flow cytometry was
carried out in FACScan and analyzed in FlowJo software.
Plaque assay
In order to determine viral load in lungs, we collected the
organs in sterile conditions and performed a plaque assay using
MDCK cells. Lungs were weighted and homogenized in PBS,
plated in MDCK monolayer and after incubation and staining it
was possible to count the plaques. The viral titer was expresses as
Plaque Forming Units (PFU) per gram of tissue.
Antibody quantification
WSN/33 H1N1 influenza virus stocks were used as antigens in
an indirect ELISA to detect specific antibodies in serum samples of
reinfected animals (Text S1).
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Statistical analysis
All data are presented as the mean 6 SEM. All data were tested
for normality and found to have a normal distribution. Normal
data were tested for significance using ANOVA followed by use of
Newman-Keuls post-test, which corrects for multiple comparisons.
Unpaired t test was used to compare two groups and Log-rank test
for lethality experiments, where appropriate. Statistical signifi-
cance was set as P,0.05 and all graphs and analysis were
performed using Graph Pad Prism 4 software.
Supporting Information
Figure S1 Pulmonary levels of inflammatory cytokines and
chemokines following mild Influenza A/WSN/33 H1N1 infection.
Mice were infected intranasally with 104 PFU of Influenza virus or
PBS (Mock) and killed 1, 4, 7 and 10 days after infection (n= 4–10
in each group). Pulmonary levels of CXCL1/KC (a), CXCL2/
MIP-2 (b), CCL2/MCP-1 (c) and TNF-a (d) were assessed by
ELISA. Data are presented as Mean 6 SEM. *, ** and *** for
p,0.05, p,0.01 and p,0.001, respectively, when compared to
Mock or indicated groups, (one-way ANOVA, Newman-Keuls).
Found at: doi:10.1371/journal.ppat.1001171.s001 (0.21 MB TIF)
Figure S2 Pulmonary levels of inflammatory cytokines and
chemokines following lethal Influenza A/WSN/33 H1N1 infec-
tion. Mice were infected intranasally with 106 PFU of Influenza
virus or PBS (Mock) and killed 1, 3 and 5 days after infection
(n = 6–7 in each group). Pulmonary levels of CXCL1/KC (a),
CXCL2/MIP-2 (b), CCL2/MCP-1 (c), TNF-a (d) were assessed
by ELISA. Data are presented as Mean 6 SEM. *, ** and *** for
p,0.05, p,0.01 and p,0.001, respectively, when compared to
Mock or indicated groups; # for p,0.05, when compared to
Mock group (one-way ANOVA, Newman-Keuls).
Found at: doi:10.1371/journal.ppat.1001171.s002 (0.19 MB TIF)
Figure S3 Mean epithelial height of bronchiole following lethal
Influenza A/WSN/33 H1N1 infection. WT and PAFR KO mice
were infected intranasally with 106 PFU of Influenza virus or PBS
(Mock) and were killed after 5 days of infection. H&E stained lung
slides were photographed under 200 fold magnification. A total of
1500 mm of bronchiolar length in areas of inflammatory infiltrates
per slide was divided in 50 mm. In every each 50 mm epithelial
height was measured. Results present the mean of the measures of
5–6 animals. Data are presented as Mean 6 SEM. ** p,0.01,
when compared to Mock groups (one-way ANOVA, Newman-
Keuls).
Found at: doi:10.1371/journal.ppat.1001171.s003 (0.11 MB TIF)
Figure S4 Inflammatory changes induced by poly(I:C) are not
PAFR dependent. WT and PAFR KO mice were instilled
intratracheally with 50 mg of poly(I:C) and killed after 8 hours.
Relative mRNA levels of LPAFAT/LPAFAT2 in lungs of PBS or
poly(I:C) instilled WT mice assessed by Real Time PCR (a).
Number of lung neutrophils, as assessed by MPO assay (b),
neutrophil influx to the airways (c) and CXCL1 levels in lungs (d)
of WT and PAFR KO mice instilled with PBS or poly(I:C). Data
are presented as Mean 6 SEM of 5–7 animals. *, ** and *** for
p,0.05, p,0.01 and p,0.001, respectively, when compared to
Mock groups; (one-way ANOVA, Newman-Keuls).
Found at: doi:10.1371/journal.ppat.1001171.s004 (0.27 MB TIF)
Text S1 Methods and legends for supporting figures.
Found at: doi:10.1371/journal.ppat.1001171.s005 (0.11 MB PDF)
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